Follow the people · Insider
Mani Mohindru
Mani Mohindru files insider transactions with the SEC as a chief executive officer of Cardiff Oncology (CRDF). We hold 2 disclosed purchases and sales filed since 25 January 2016, 2 of them in the last 90 days.
- Files forCRDF
- Disclosed buys and sells2 in all, 2 in the last 90 days
- Last disclosure16 July 2026
Positions held
4 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 10 June 2021 — 14 July 2026Chief Executive Officer · Cardiff Oncology (CRDF)11 Form 4 lines · source: SEC Form 4
- Filed 16 December 2020 — 17 June 2026Director · CytomX Therapeutics (CTMX)7 Form 4 lines · source: SEC Form 4
- Filed 15 August 2017 — 4 December 2019CFO & Chief Strategy Officer · Cara Therapeutics (CARA)20 Form 4 lines · source: SEC Form 4
- Filed 19 January 2016 — 14 February 2017Chief Strategy Officer · Curis (CRIS)3 Form 4 lines · source: SEC Form 4
Everything they disclosed
41 entries, newest first — one per disclosure report, one per Form 4 line- ▲ bought on the open market 34,364 shares of Cardiff OncologySEC Form 416 July 2026Common Stock · traded 14 July 2026 · filed 16 July 2026
- ▲ bought on the open market 34,364 shares of Cardiff Oncology (a derivative holding)SEC Form 416 July 2026Common Stock Purchase Warrant · traded 14 July 2026 · filed 16 July 2026
- was granted 59,000 shares of CytomX Therapeutics (a derivative holding)SEC Form 422 June 2026Stock Option (Right to Buy) · traded 17 June 2026 · filed 22 June 2026
- ▲ bought on the open market 24,703 shares of Cardiff OncologySEC Form 422 June 2026Common Stock · traded 18 June 2026 · filed 22 June 2026
- was granted 600,000 shares of Cardiff Oncology (a derivative holding)SEC Form 42 April 2026Stock Options · traded 31 March 2026 · filed 2 April 2026
- was granted 200,000 shares of Cardiff Oncology (a derivative holding)SEC Form 418 February 2026Stock Options · traded 17 February 2026 · filed 18 February 2026
- was granted 200,000 shares of Cardiff Oncology (a derivative holding)SEC Form 418 February 2026Stock Options · traded 17 February 2026 · filed 18 February 2026
- was granted 40,565 shares of Cardiff Oncology (a derivative holding)SEC Form 430 June 2025Stock Options · traded 26 June 2025 · filed 30 June 2025
- was granted 38,000 shares of CytomX Therapeutics (a derivative holding)SEC Form 413 June 2025Stock Option (Right to Buy) · traded 11 June 2025 · filed 13 June 2025
- was granted 29,700 shares of Cardiff Oncology (a derivative holding)SEC Form 41 July 2024Stock Options · traded 27 June 2024 · filed 1 July 2024
- was granted 38,000 shares of CytomX Therapeutics (a derivative holding)SEC Form 417 May 2024Stock Option (Right to Buy) · traded 15 May 2024 · filed 17 May 2024
- was granted 27,700 shares of Cardiff Oncology (a derivative holding)SEC Form 420 June 2023Stock Options · traded 15 June 2023 · filed 20 June 2023
- was granted 25,000 shares of CytomX Therapeutics (a derivative holding)SEC Form 416 June 2023Stock Option (Right to Buy) · traded 14 June 2023 · filed 16 June 2023
- was granted 25,000 shares of CytomX Therapeutics (a derivative holding)SEC Form 417 June 2022Stock Option (Right to Buy) · traded 15 June 2022 · filed 17 June 2022
- was granted 26,800 shares of Cardiff Oncology (a derivative holding)SEC Form 410 March 2022Stock Options · traded 9 March 2022 · filed 10 March 2022
- was granted 20,000 shares of CytomX Therapeutics (a derivative holding)SEC Form 417 June 2021Stock Option (Right to Buy) · traded 16 June 2021 · filed 17 June 2021
- was granted 44,001 shares of Cardiff Oncology (a derivative holding)SEC Form 414 June 2021Stock Options · traded 10 June 2021 · filed 14 June 2021
- was granted 40,000 shares of CytomX Therapeutics (a derivative holding)SEC Form 418 December 2020Stock Option (Right to Buy) · traded 16 December 2020 · filed 18 December 2020
- was granted 8,333 shares of Cara TherapeuticsSEC Form 44 December 2019Common Stock · traded 2 December 2019 · filed 4 December 2019
- ▼ sold on the open market 4,755 shares of Cara TherapeuticsSEC Form 44 December 2019Common Stock · traded 4 December 2019 · filed 4 December 2019
- exercised options over 37,431 shares of Cara Therapeutics (a derivative holding)SEC Form 417 July 2019Employee Stock Option (Right to Buy) · traded 15 July 2019 · filed 17 July 2019
- exercised options over 37,431 shares of Cara TherapeuticsSEC Form 417 July 2019Common Stock · traded 15 July 2019 · filed 17 July 2019
- ▼ sold on the open market 37,431 shares of Cara TherapeuticsSEC Form 417 July 2019Common Stock · traded 15 July 2019 · filed 17 July 2019
- was granted 8,333 shares of Cara TherapeuticsSEC Form 430 May 2019Common Stock · traded 28 May 2019 · filed 30 May 2019
- ▼ sold on the open market 2,496 shares of Cara TherapeuticsSEC Form 430 May 2019Common Stock · traded 29 May 2019 · filed 30 May 2019
- exercised options over 16,041 shares of Cara Therapeutics (a derivative holding)SEC Form 415 March 2019Employee Stock Option (Right to Buy) · traded 13 March 2019 · filed 15 March 2019
- exercised options over 16,041 shares of Cara TherapeuticsSEC Form 415 March 2019Common Stock · traded 13 March 2019 · filed 15 March 2019
- ▼ sold on the open market 16,041 shares of Cara TherapeuticsSEC Form 415 March 2019Common Stock · traded 13 March 2019 · filed 15 March 2019
- was granted 75,000 shares of Cara Therapeutics (a derivative holding)SEC Form 48 March 2019Employee Stock Option (Right to Buy) · traded 6 March 2019 · filed 8 March 2019
- ▼ sold on the open market 4,500 shares of Cara TherapeuticsSEC Form 42 January 2019Common Stock · traded 28 December 2018 · filed 2 January 2019
- was granted 12,526 shares of Cara TherapeuticsSEC Form 431 December 2018Common Stock · traded 27 December 2018 · filed 31 December 2018
- exercised options over 16,042 shares of Cara Therapeutics (a derivative holding)SEC Form 416 November 2018Employee Stock Option (Right to Buy) · traded 15 November 2018 · filed 16 November 2018
- exercised options over 16,042 shares of Cara TherapeuticsSEC Form 416 November 2018Common Stock · traded 15 November 2018 · filed 16 November 2018
- ▼ sold on the open market 16,042 shares of Cara TherapeuticsSEC Form 416 November 2018Common Stock · traded 15 November 2018 · filed 16 November 2018
- exercised options over 16,042 shares of Cara Therapeutics (a derivative holding)SEC Form 419 October 2018Employee Stock Option (Right to Buy) · traded 17 October 2018 · filed 19 October 2018
- exercised options over 16,042 shares of Cara TherapeuticsSEC Form 419 October 2018Common Stock · traded 17 October 2018 · filed 19 October 2018
- ▼ sold on the open market 16,042 shares of Cara TherapeuticsSEC Form 419 October 2018Common Stock · traded 17 October 2018 · filed 19 October 2018
- was granted 385,000 shares of Cara Therapeutics (a derivative holding)SEC Form 424 August 2017Employee Stock Option (Right to Buy) · traded 15 August 2017 · filed 24 August 2017
- was granted 424,000 shares of Curis (a derivative holding)SEC Form 416 February 2017Employee stock option (right to buy) · traded 14 February 2017 · filed 16 February 2017
- was granted 200,000 shares of Curis (a derivative holding)SEC Form 430 March 2016Employee stock option (right to buy) · traded 29 March 2016 · filed 30 March 2016
- was granted 100,000 shares of Curis (a derivative holding)SEC Form 425 January 2016Employee stock option (right to buy) · traded 19 January 2016 · filed 25 January 2016
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.